Skip to Content
Merck
CN

SML4229

BI 2536

≥98% (HPLC), powder, Plk1 inhibitor

Synonym(s):

4-[[(7R)-8-Cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide, (R)-4-[(8-Cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide, BI-2536, BI-2536,Polo-like Kinase Inhibitor IV

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C28H39N7O3
CAS Number:
Molecular Weight:
521.65
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

O=C(NC1CCN(C)CC1)C2=CC=C(NC(N=C3N(C4CCCC4)[C@@H]5CC)=NC=C3N(C)C5=O)C(OC)=C2

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Application

BI 2536 may be used in targeting polo-like kinase 1 (PLK1) in cancer therapy; and studying its role in neuroblastoma.

Biochem/physiol Actions

BI 2536 is an ATP-competitive, potent and selective polo-like kinase 1 (Plk1) inhibitor (Plk1/2/3 IC50 = 0.83/3.5/9.0 nM; [ATP] = 7.5 µM) that induces mitotic arrest and apoptosis in human cancer cultures (EC50 <100 nM among 32 different cancer lines) and suppresses human cancer xenografts tumor growth in nude mice in vivo (50-60 mg/kg i.v. twice weekly on two consecutive days; HCT116 and NCI-H460).

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Péter Lénárt et al.
Current biology : CB, 17(4), 304-315 (2007-02-13)
The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensively to further understanding of mitotic mechanisms and as potential targets for cancer therapy. Cdk1 and Aurora kinase studies have been facilitated by small-molecule inhibitors, but
Martin Steegmaier et al.
Current biology : CB, 17(4), 316-322 (2007-02-13)
Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery. As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly
Mark Petronczki et al.
Developmental cell, 12(5), 713-725 (2007-05-10)
Cytokinesis of animal cells requires ingression of the actomyosin-based contractile ring between segregated sister genomes. Localization of the RhoGEF Ect2 to the central spindle at anaphase promotes local activation of the RhoA GTPase, which induces assembly and ingression of the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service